EUCTR2009-012603-26-FR进行中（未招募）1 期
A randomised, double-blind study evaluating the safety, tolerability and clinical outcome of Neoven compared to Vaminolact in premature ELBW infants
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 17
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- Sex: Male or female
- •- Birth weight: = 1000 g
- •- Gestational age: = 29^6/7 weeks
- •- Age: < 48 hours after birth
- •- Life expectation should be at least 6 days as of start of PN
- •- Estimated requirement of parenteral nutrition (PN) including amino acids for at least 6 days
- •- Legal representative(s) signed and dated Informed Consent
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Severe congenital malformations [like gastroschisis, omphalocele, syndrome associated with (suspected) chromosomal anomalies, severe hydrops fetalis]
- •- Insufficient renal function with serum creatinine of = 2.0 mg/dL (= 120 µmol/L) or receiving dialysis/hemofiltration therapy.
- •- Severe liver dysfunction with either ammonia levels > 150 µmol/L or total bilirubin >8 mg/dl and ALT > 200 lU/L.
- •- Severe congenital heart disease
- •- Haematolytic disease and hyperbilirubinemia requiring exchange infusion
- •- Oxygen saturation SpO2 < 80% for longer than two hours
- •- Severe thrombocytopenia: platelets < 30x10^9/L
- •- Administration of catecholamines except:
- •- low dose dopamine = 10 µg/kg bw/min and/or
- •- dobutamine = 10 µg/kg bw/min or
- •- adrenaline = 0.2 µg/kg bw/min
- •- Congenital metabolic and/or endocrinologic disorders that affect energy and nutrient metabolism (e.g. errors of amino acid metabolism)
- •- Severe metabolic acidosis (pH < 6.9 and base excess (BE = -15 mmol/L) after 6 hours of life
- •- Oral/Enteral nutrition with more than 20% of total energy intake at the beginning of amino acid supplementation
- •- Participation in another interventional clinical trial since birth
研究者
相似试验
进行中（未招募）
1 期
A randomised, double-blind study evaluating the safety, tolerability and clinical outcome of Neoven compared to Vaminolact in premature ELBW infantsThe product is aimed to be used where parenteral nutrition is required. The intended indication is: Supply of essential and non-essential amino acids as part of Parenteral Nutrition for premature extreme low birth weight (ELBW) infants, when oral or enteral nutrition is impossible, insufficient or contraindicated.MedDRA version: 12.1 Level: LLT Classification code 10051284 Term: Parenteral nutritionEUCTR2009-012603-26-BEFresenius Kabi Deutschland GmbH17
进行中（未招募）
不适用
A randomised, double-blind study evaluating the safety, tolerability, and amino acid plasma levels of Neoven compared to Vaminolact in infants after surgical interventions.The product is aimed to be used where parenteral nutrition is required.The indended indication is: Supply of essential and non-essential amino acids as part of parenteral nutrition for preterm and fullterm neonates, infants and children, when oral or enteral nutrition is impossible, insufficient or contraindicated.MedDRA version: 9.1Level: LLTClassification code 10051284Term: Parenteral nutritionEUCTR2008-000429-20-NLFresenius Kabi Deutschland GmbH18
进行中（未招募）
不适用
A randomised, double-blind study evaluating the safety, tolerability, and amino acid plasma levels of Neoven compared to Vaminolact in infants after surgical interventions.The product is aimed to be used where parenteral nutrition is required.The indended indication is: Supply of essential and non-essential amino acids as part of parenteral nutrition for preterm and fullterm neonates, infants and children, when oral or enteral nutrition is impossible, insufficient or contraindicated.MedDRA version: 9.1Level: LLTClassification code 10051284Term: Parenteral nutritionEUCTR2008-000429-20-BEFresenius Kabi Deutschland GmbH18
已完成
3 期
A randomised, double-blind study evaluating the safety, tolerability, protein accretion, amino acid plasma levels and long-term outcome of Neoven compared to Vaminolact in premature very low birth weigth (VLBW) infants.need for parenteral foodneed of food through infusion when feeding through the mouth is not posible10037008NL-OMON34823Fresenius Kabi Deutschland GmbH110
进行中（未招募）
不适用
A randomised, double-blind study evaluating the safety, tolerability, and amino acid plasma levels of Neoven compared to Vaminolact in infants after surgical interventions.EUCTR2008-000429-20-DEFresenius Kabi Deutschland GmbH18